Publications by authors named "Feagan Brian"

Claim this Profile
S
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial.
Vipul Jairath, Silvio Danese, Geert R D'Haens, Brian G Feagan, Laurent Peyrin-Biroulet

Lancet Gastroenterol Hepatol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn's Disease.
Stefan Schreiber, Scott D Lee, C Janneke van der Woude, Ignacio Marín-Jiménez, Douglas C Wolf, Brian G Feagan

Inflamm Bowel Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease.
Silvio Danese, Bruce E Sands, Brian G Feagan, Vipul Jairath, Remo Panaccione

Contemp Clin Trials Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease.
Jurij Hanžel, Virginia Solitano, Sudheer Kumar Vuyyuru, Remo Panaccione, Bruce E Sands, Brian Bressler, Brian G Feagan

Gastroenterology· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crohn Disease Strictures: Multimodality Imaging to Identify Imaging Biomarkers.
Safa Hoodeshenas, Jonathan R Dillman, Stuart A Taylor, Jordi Rimola, Bachir Taouli, Brian Feagan

Radiographics· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Placebo rates in randomized clinical trials of ulcerative colitis: an individual patient data meta-analysis.
Virginia Solitano, Malcolm Hogan, Siddharth Singh, Silvio Danese, Laurent Peyrin-Biroulet, Brian G Feagan

J Crohns Colitis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An international consensus on the design of clinical trials for advanced combination treatment (ACT) in inflammatory bowel disease.
Virginia Solitano, Jurij Hanžel, Christopher Ma, Robert Battat, Tim Raine, Brian G Feagan

EClinicalMedicine· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations to Standardize the Conduct of Clinical Trials Evaluating Novel Therapies for Perianal Fistulizing Crohn's Disease.
Sudheer Kumar Vuyyuru, Jurij Hanzel, Mantaj S Brar, Silvio Danese, Geert D'Haens, Brian G Feagan

Clin Gastroenterol Hepatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An evaluation of guselkumab for the treatment of ulcerative colitis.
Jurij Hanzel, Vipul Jairath, Brian G Feagan

Expert Opin Biol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial.
Silvio Danese, Jessica R Allegretti, Stefan Schreiber, Laurent Peyrin-Biroulet, Vipul Jairath, Brian G Feagan

Lancet Gastroenterol Hepatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How Should an IBD Prevention Trial Be Designed?
Rogier L Goetgebuer, Ryan C Ungaro, Brian G Feagan, Vipul Jairath, Jean-Frédéric Colombel

Inflamm Bowel Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reliability and Responsiveness of Endoscopic Indices for Assessing Crohn's Disease Postoperative Recurrence in the PREVENT trial.
Jurij Hanzel, Sudheer K Vuyyuru, Brian Bressler, Mark A Samaan, Malcolm Hogan, Brian G Feagan

Clin Gastroenterol Hepatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.
Brian G Feagan, Bruce E Sands, Corey A Siegel, Marla C Dubinsky, Randy S Longman

Lancet Gastroenterol Hepatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of a novel Endoscopic ulcer Activity Score for Evaluation of Crohn's Disease (EASE-CD) using data from two randomised controlled trials.
Christopher Ma, Reena Khanna, Bryan R Maguire, Guangyong Zou, Brian Bressler, Brian G Feagan

Lancet Gastroenterol Hepatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2 Study of MORF-057, an Oral α4β7 Integrin Inhibitor in Moderately to Severely Active Ulcerative Colitis.
Bruce E Sands, Stefan Schreiber, Silvio Danese, Jarosław Kierkus, Brihad Abhyankar, Brian G Feagan

Clin Gastroenterol Hepatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with response to filgotinib and the prognostic power of faecal calprotectin for ulcerative colitis in the phase 2b/3 SELECTION trial.
Edouard Louis, Stefan Schreiber, Tadakazu Hisamatsu, Toshifumi Hibi, Corinne Jamoul, Brian G Feagan

Dig Liver Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and External Validation of an Endoscopic and Histologic Pouchitis Assessment Tool: The Atlantic Pouchitis Index.
Rocio Sedano, Christopher Ma, Malcolm Hogan, Mark S Silverberg, Guangyong Zou, Brian Bressler, Brian G Feagan

Clin Gastroenterol Hepatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials.
Remo Panaccione, Brian G Feagan, Anita Afzali, David T Rubin, Walter Reinisch

Lancet· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ambroxol as a Treatment for Parkinson Disease Dementia: A Randomized Clinical Trial.
Carolina R A Silveira, Kristy K L Coleman, Kathy Borron, Rommel G Tirona, Charles A Rupar, Brian Feagan

JAMA Neurol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic Comparability and Safety Between Original and Citrate-Free Mirikizumab Formulations for Subcutaneous Injections: Results from Three Clinical Trials.
Yuki Otani, Brian G Feagan, Geert R D'Haens, Rodrigo Escobar, Nathan J Morris

Adv Ther· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of bile acid diarrhea with symptoms and disease activity in Crohn's disease: post-hoc clinical trial analysis of serum 7a-hydroxy-4cholestern-3-one, C4, in patients with active Crohn's disease.
Robert Battat, Soumya Kandi, Ana P Lacerda, Phil Levine, Ezequiel Neimark, Brian G Feagan

J Crohns Colitis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert recommendations to standardize transcriptomic analysis in inflammatory bowel disease clinical trials.
Bryan Linggi, Salas Azucena, Boyd Steere, Bram Verstockt, Dahham Alsoud, Brian G Feagan

J Crohns Colitis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis and Management of Upper Gastrointestinal Involvement in Adult Patients With Crohn's Disease: A Systematic Review.
Nathaniel A Cohen, Neta Sror, Maliha Naseer, Dominik Bettenworth, Cathy Lu, Brian Feagan

Clin Gastroenterol Hepatol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definitions, diagnosis, and management of postoperative recurrence in Crohn's disease patients with permanent ileostomy-a systematic review and meta-analysis.
Suha Abushamma, Tesfaye Yadete, Neil Nero, Katherine Falloon, Claire E Parker, Brian G Feagan

J Crohns Colitis· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn's Disease.
Brian G Feagan, Remo Panaccione, Stefan Schreiber, Edward V Loftus, Laurent Peyrin-Biroulet

Gastro Hep Adv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis